ZymeTx, Inc. - ZMTX new biotech company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymeTx, Inc. - ZMTX new biotech company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: O. H. Rundell who wrote (34)	12/19/1997 5:40:00 PM
From: Tyndall	Read Replies (1) of 88

ComVest Partners, Inc. Initiate Coverage of ZymeTx, Inc. DALLAS--(BUSINESS WIRE)--Dec. 19, 1997--ComVest Partners, Inc., initiated coverage of ZymeTx, Inc. (Nasdaq:ZMTX - news) with a BUY rating. In a research report by William J. Hoffman M.D., the firm estimated ZymeTX, Inc. will earn $0.43 a share for fiscal year ending June 1998 and $2.10 a share for fiscal 1999. ZymeTx, Inc. is the pioneer in the production of a FDA approved point-of-care test for the diagnosis of ''The Flu.'' The product which is called ZstatFlu is available and will be sold during the current flu season which is occurring from December 1997 to March 1998. ZymeTx, Inc. is located in Oklahoma City.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next